









市场行情
/
股票
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

10.720USD

+0.220+2.10%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.13B总市值

亏损市盈率 TTM



Biohaven Ltd

10.720

+0.220+2.10%

概览公司财务分析

概览

公司

财务

分析

关于 Biohaven Ltd 公司

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Biohaven Ltd简介



公司代码BHVN

公司名称Biohaven Ltd

上市日期Sep 23, 2022

CEOCoric (Vlad)

员工数量256

证券类型Ordinary Share

年结日Sep 23

公司地址215 Church Street

城市NEW HAVEN

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家United States of America

邮编06510

电话12034040410

网址https://www.biohaven.com/

公司代码BHVN

上市日期Sep 23, 2022

CEOCoric (Vlad)

Biohaven Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

2.02M

+24.69%

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

Dr. Irina Antonijevic, M.D., Ph.D.

Independent Director

Mr. John W. Childs

Independent Director

Dr. Vlad Coric, M.D.

Chairman of the Board, Chief Executive Officer

Ms. Kimberly Gentile

Senior Vice President of Clinical Operations

名称

名称/职务

职务

持股

持股变动

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

2.02M

+24.69%

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Janus Henderson Investors

5.11%

1919 Investment Counsel, LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.94%

Childs John W

4.91%

Suvretta Capital Management, LLC

4.24%

其他

75.83%

持股股东

占比

Janus Henderson Investors

5.11%

1919 Investment Counsel, LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.94%

Childs John W

4.91%

Suvretta Capital Management, LLC

4.24%

其他

75.83%

股东类型

持股股东

占比

Investment Advisor

25.60%

Investment Advisor/Hedge Fund

20.43%

Hedge Fund

13.94%

Individual Investor

9.18%

Research Firm

3.29%

Sovereign Wealth Fund

0.68%

Venture Capital

0.41%

Corporation

0.38%

Pension Fund

0.35%

其他

25.75%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

573

86.14M

79.56%

+56.74K

2025Q3

585

86.08M

100.43%

-2.05M

2025Q2

570

88.15M

95.46%

-3.76M

2025Q1

560

91.76M

98.48%

-8.79M

2024Q4

552

92.88M

95.24%

+5.30M

2024Q3

538

88.35M

95.17%

+3.19M

2024Q2

505

84.45M

87.45%

+8.19M

2024Q1

484

76.13M

96.08%

-2.46M

2023Q4

433

73.36M

88.24%

+6.86M

2023Q3

386

63.55M

100.60%

+1.17M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Janus Henderson Investors

5.05M

4.78%

-1.38M

-21.51%

Jun 30, 2025

1919 Investment Counsel, LLC

6.60M

6.23%

+2.50K

+0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.44M

6.08%

+113.23K

+1.79%

Jun 30, 2025

Childs John W

6.51M

6.15%

+351.58K

+5.71%

Mar 10, 2025

Suvretta Capital Management, LLC

5.62M

5.31%

Jun 30, 2025

State Street Investment Management (US)

3.54M

3.34%

+115.81K

+3.38%

Jun 30, 2025

Coric (Vladimir)

3.18M

+26.57K

+0.84%

Mar 10, 2025

The Vanguard Group, Inc.

9.23M

8.72%

+828.80K

+9.87%

Jun 30, 2025

Bellevue Asset Management AG

2.80M

2.65%

+762.00K

+37.34%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.66M

1.57%

-246.36K

-12.89%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

2.64%

Roundhill GLP-1 & Weight Loss ETF

2.18%

Simplify Health Care ETF

1.58%

Virtus LifeSci Biotech Clinical Trials ETF

0.75%

State Street SPDR S&P Biotech ETF

0.69%

Direxion Daily S&P Biotech Bull 3X Shares

0.42%

WisdomTree BioRevolution Fund

0.33%

Optimize Strategy Index ETF

0.24%

Inspire Small/Mid Cap ESG ETF

0.24%

JPMorgan Fundamental Data Science Small Core ETF

0.2%

iShares Neuroscience and Healthcare ETF

占比2.64%

Roundhill GLP-1 & Weight Loss ETF

占比2.18%

Simplify Health Care ETF

占比1.58%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.75%

State Street SPDR S&P Biotech ETF

占比0.69%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.42%

WisdomTree BioRevolution Fund

占比0.33%

Optimize Strategy Index ETF

占比0.24%

Inspire Small/Mid Cap ESG ETF

占比0.24%

JPMorgan Fundamental Data Science Small Core ETF

占比0.2%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Biohaven Ltd的前五大股东是谁？



Biohaven Ltd 的前五大股东如下：
Janus Henderson Investors持有股份：5.05M，占总股份比例：4.78%。
1919 Investment Counsel, LLC持有股份：6.60M，占总股份比例：6.23%。
BlackRock Institutional Trust Company, N.A.持有股份：6.44M，占总股份比例：6.08%。
Childs John W持有股份：6.51M，占总股份比例：6.15%。
Suvretta Capital Management, LLC持有股份：5.62M，占总股份比例：5.31%。